June 19, 2008

Terumo Announces Acquisition of Shares of Clinical Supply Co., Ltd.

Terumo Corporation (Shibuya-ku, Tokyo, Japan; President: Akira Takahashi, “Terumo”) today announced that it has agreed with Eisai Co., Ltd. (Bunkyo-ku, Tokyo, Japan; President: Haruo Naito, “Eisai”) that Terumo will receive all the shares of Clinical Supply Co., Ltd. (Kakamigahara-shi, Gifu, Japan; President: Muneyuki Naka, “Clinical Supply”), a subsidiary of Eisai, held by Eisai (84.8% of the outstanding shares of Clinical Supply), thus making Clinical Supply a Terumo subsidiary.

Accordingly, it is planned to change Clinical Supply’s name to Terumo Clinical Supply Co., Ltd. from January 2009.

1. Objective

Clinical Supply manufactures medical devices, principally intervention products, with integrated operations from development and manufacturing to sales.  It is particularly strong in products chiefly used in the radiology field, such as angiographic catheters and microcatheters, and operates throughout Japan.

Terumo sees intervention products, which allow various diagnoses and treatments to be performed via blood vessels, as one of its most important growth businesses, globally provides a wide range of products, centered on the cardiology and radiology fields, such as guidewires, angiographic catheters, and PTCA balloon catheters.

The addition of Clinical Supply will strengthen the Terumo Group’s intervention business within Japan centered on the radiology fields and is expected to lead to a global expansion making use of Terumo’s overseas bases.  The companies will also proactively engage in development of new products that make use of the respective strengths of each company and enhance the growth of the business over the medium and long terms.

2. Outline of Clinical Supply

1. Name: Clinical Supply Co., Ltd.
2. Representative: Muneyuki Naka, President
3. Head Office: Kawashimatakehaya-machi 3, Kakamigahara-shi, Gifu, Japan
4. Established: 1968
5. Principal Business: R&D and manufacturing and sales for medical devices
6. Number of Employees: 215 (as of April 1, 2008)
7. Capital:80 million yen
8. Sales: 2.9 billion yen (results for year ended March 31, 2007)

3. Share Acquisition Schedule

Acquisition of all shares held by Eisai: June 30, 2008 (planned)

4. Impact on Results

The impact of this deal on results will be limited, and there will be no change to the forecasts for the current period.

Reference:

Outline of Terumo

1. Name: Terumo Corporation
2. Representative: Akira Takahashi, Representative Director & President
3. Head Office: 44-1 Hatagaya 2-chome, Shibuya-ku, Tokyo, Japan
4. Established: 1921
5. Principal Business: Manufacture and sales of medical devices and pharmaceuticals.
6. Number of Employees: 12,322 (consolidated basis as of March 31, 2008)
7. Capital: 38.7 billion yen
8. Sales: 306.4 billion yen (consolidated basis as of March 31, 2008)

Outline of Eisai

1. Name: Eisai Co., Ltd.
2. Representative: Haruo Naito, President and CEO
3. Head Office: 6-10 Koishikawa 4-chome, Bunkyo-ku, Tokyo, Japan
4. Established: 1941
5. Principal Business: R&D, manufacturing, sales and import and export of pharmaceuticals.
6. Number of Employees: 10,686 (consolidated basis as of March 31, 2008)
7. Capital: 44.9 billion yen
8. Sales: 734.2 billion yen (consolidated basis as of March 31, 2008)

(Note) Forward-looking statements included in this release were determined by Terumo based on the best information available at the time of writing and are subject to potential risks and uncertainties. Therefore, please note that, due to various factors, the actual implementation may differ from what is described here.

• 
•